A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
about
Hepatitis C virus Broadly Neutralizing Monoclonal Antibodies Isolated 25 Years after Spontaneous ClearanceReverse epitope mapping of the E2 glycoprotein in antibody associated hepatitis C virus.Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.Extra-epitopic hepatitis C virus polymorphisms confer resistance to broadly neutralizing antibodies by modulating binding to scavenger receptor B1Broad Anti-Hepatitis C Virus (HCV) Antibody Responses Are Associated with Improved Clinical Disease Parameters in Chronic HCV InfectionViral evasion and challenges of hepatitis C virus vaccine development.Structure-Based Design of Hepatitis C Virus Vaccines that Elicit Neutralizing Antibody Responses to a Conserved Epitope.Novel functional hepatitis C virus glycoprotein isolates identified using an optimized viral pseudotype entry assay.Hepatitis C virus resistance to broadly neutralizing antibodies measured using replication-competent virus and pseudoparticles.Flexible and rapid construction of viral chimeras applied to hepatitis C virus.A novel neutralizing human monoclonal antibody broadly abrogates hepatitis C virus infection in vitro and in vivo.Probing the antigenicity of hepatitis C virus envelope glycoprotein complex by high-throughput mutagenesis.Designing a B Cell-Based Vaccine against a Highly Variable Hepatitis C Virus.Predicting the Effectiveness of Hepatitis C Virus Neutralizing Antibodies by Bioinformatic Analysis of Conserved Epitope Residues Using Public Sequence Data.Defining Breadth of Hepatitis C Virus NeutralizationHepatitis C Virus Envelope Glycoproteins: A Balancing Act of Order and Disorder
P2860
Q28552909-9912E4B8-1D3E-4B46-B1B7-476A869C762EQ33739145-5EC621C2-132E-48A5-91FF-CC8A0AE32F12Q36288404-DADA005B-2ECA-4FF0-A82C-B5E5C55A670AQ36290295-C0AFC191-C008-4DAB-8993-B9D619CEFFF2Q36811958-80235992-1B15-4036-AB8A-A6987F3C9851Q38961608-2CAF1FFE-04D5-40D1-84BC-0B055E6C8A6DQ40088796-EADC37EE-A598-48D6-9CA4-4FDC36138B73Q40098163-CDE6BCD5-1810-44EA-9CD1-37EB2D01CFDCQ40527984-FFAD4A8B-6284-422D-AACD-D7690762EA06Q40688888-C71DD748-F38A-40C6-B8BA-CE7FA20655FAQ45325612-E33A4773-8D7D-4A16-AFAA-743F99D0778EQ47238536-A0FA88F4-2E60-4E10-854E-6EB8E6FE05F4Q47548062-9718F933-E9D6-4812-8E1E-FAFB7A8BC378Q55657826-CE78BA44-96F3-4359-8D8D-7A46BDF2175AQ56395915-1E8A653E-B671-4187-AF61-694CBB51D2C0Q57265415-5891DFD8-ABC8-4941-BEEA-ACEFB1D82E2F
P2860
A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
A Diverse Panel of Hepatitis C ...... ody Neutralization Resistance.
@en
type
label
A Diverse Panel of Hepatitis C ...... ody Neutralization Resistance.
@en
prefLabel
A Diverse Panel of Hepatitis C ...... ody Neutralization Resistance.
@en
P2860
P50
P356
P1433
P1476
A Diverse Panel of Hepatitis C ...... body Neutralization Resistance
@en
P2093
C Patrick McClure
Thomas Krey
P2860
P304
P356
10.1128/JVI.02700-15
P407
P50
P577
2015-12-23T00:00:00Z